NEW YORK (GenomEWeb News) - CombiMatrix said today that it will provide chromosomal microarray analysis-based testing for miscarriage analysis for ProPath, a pathology services provider.

The agreement enables ProPath to add a new product to its suite of women's health diagnostics, one that "can play a significant role in a comprehensive miscarriage analysis," according to Kenneth Youens, ProPath's women's health director. He added that "the accuracy, clinical utility and quick turnaround times of CMA testing makes it a superior first tier testing option."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.